International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Correlation between Hemoglobin A1c Levels and Microvascular Complications in Type 2 Diabetes

Hala F. Almeshari[1], Mahasen O. Aljehani[2], Wedad M. Almutairi[3], Amera A. Alqahtani[4], Hala H. Al Mutairi[5], Abdulaziz S. Alaws[6], Nujud K. Hajij[7], Freh A. Alfreh[8], Ruba K. Alhammad[9], Sara S. Alhamdan[10]

Health Affairs at the Ministry of National Guard

Abstract

Background: Microvascular complications, including diabetic retinopathy (DR), nephropathy (DN), and neuropathy, are significant contributors to morbidity in patients with type 2 diabetes mellitus (T2DM). Glycated hemoglobin (HbA1c) serves as a key marker of glycemic control and has been implicated in the development of these complications.

Objective: This study investigates the correlation between HbA1c levels and the prevalence of microvascular complications in patients with T2DM in a tertiary care hospital.

Methods: A retrospective observational study was conducted on 400 T2DM patients. Patients were stratified into three groups based on HbA1c levels (<7%, 7–9%, >9%). The prevalence of DR, DN, and neuropathy was analyzed, and logistic regression was used to assess the association between HbA1c levels and complications.

Results: Higher HbA1c levels were associated with a significantly greater prevalence of microvascular complications. Patients with HbA1c >9% had the highest prevalence of DR (60%), DN (55%), and neuropathy (50%). Logistic regression revealed strong correlations between HbA1c levels and complications, with odds ratios of 2.1 for DR, 3.2 for DN, and 4.0 for neuropathy ($p < 0.01$).

Conclusion: This study demonstrates a robust correlation between HbA1c levels and microvascular complications in T2DM, underscoring the importance of optimal glycemic control. These findings support individualized glycemic targets to reduce complication risk.

Keywords: Type 2 diabetes mellitus, HbA1c, microvascular complications, diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, glycemic control

Introduction

Type 2 diabetes mellitus (T2DM) is one of the most challenging conditions to manage globally due to chronic hyperglycemia resulting from insulin secretion and action defects, or both. A patient's morbidity

and mortality regarding T2DM is mostly influenced by the long-standing complications with microvacular complications being extremely worrying. In particular, the complications of diabetes such as diabetic retinopathy (DR), diabetic nephropathy (DN), and neuropathy tend to be associated with poor glycemic control which is commonly assessed through the measurement of glycated hemoglobin (Teliti et al., 2018).

HbA1c can be accurately used to gauge glucose blood concentrations in the previous 2 three months making it integral in the estimation of glycemic control. A number of researchers have reported poor glycemic control from elevated HbA1C levels, to be linked with heightened microvascular complications of T2DM. (Klein et al., 1996). In addition to that, it has been proven that the expense of these complications is greater in people with HbA1C values above 7% which makes the situation even worse. (Timar&Albai, 2012).

The association that exists seems to be owing to the complex interplay of physiological mechanisms including oxidative stress from glucosylation, microvascular endothelial dysfunction, and the formation of advanced glycation end product (AGE). This chain of events leads to the damaging and functional impairment of tissues such as those in the peripheral nerves, eyes, and kidneys. (Hirsch & Brownlee, 2010).

More studies have focused on the assessment of the relationship between microvascular complications and glycemic variability and most of the studies point to the need for moderation of not only HbA1c levels but also blood glucose levels (Zhao et al., 2015). Regardless, there is still discussion regarding the appropriate glycemic levels that would provide the greatest benefit in terms of reducing complications (Zoungas et al., 2012).

This study is intended to assess the association of microvascular complications with HbA1c levels among T2DM patients. The study will determine the association of levels of control of glycemia with the onset of DR, DN, and other forms of neuropathy and formulate the management of precise glycemic targets in T2DM.

Literature Review

The connection between hemoglobin A1c (HBA1c) levels, which indicate the status of one's glycemic control, and the likelihood of developing microvascular complications in type 2 diabetes mellitus (T2DM) patients has been the focus of diabetic studies for years. It encompasses microvascular complications such as diabetic retinopathy (DR), diabetic nephropathy (DN), and diabetic neuropathy. All of these have advanced effects in T2DM patients that are uncontrolled. A multitude of studies have investigated the association of HbA1c in these complications and have identified it as a biomarker that determines the level of long-term glycemic control.

For the previous one to two months, HbA1c corresponds with the mean blood glucose level and its concentration is proportional to the severity of chronic diabetes complications. For example, Teliti et al. (2018) examined the range of factors associated with the progression of diabetic microvascular

complications and stressed that high HBA1c levels served as one of the critical determinants. This is consistent with Klein et al. 1996, who found that poor glycemic control led to greater incidences above DR, DN, and neuropathy.

One area that requires further research is the glycemic thresholds which provide maximum benefits and minimum risks. As noted by Timar and Albai (2012), the frequency of microvascular complications jumped significantly when prevalence of HbA1c levels went above 7%. This indicates that controlling blood sugar levels more tightly could help reduce the associated risks. However, the maximum level of control is always patient-specific due to facilities as well as the risk of hypoglycemia. Zounzas et al (2012) furthered this perspective by demonstrating that the risk of vascular complications, be they micro or macro, have a clear link to the prevalence of HbA1c.

This relationship is grounded on the tissue damaging consequences of hyperglycemia induced oxidative stress alongside dysfunctional endothelium which compromises microvascular integrity. Hirsh and Brownlee (2010) included in their argument that an improved approach to incorporating risk for microvascular complications should include more than just HbA1c levels. More current reports have amplified the importance of glycemic variability, capturing the mean value of HbA1c is insufficient for understanding impacts, arguing tht it should be treated as a risk factor. Zhao et al. (2015) for example describes the glycemic variability and its significance on DR and DN argue the need for much more nuanced approaches.

Moreover, certain research has been done on other comorbidities that may contribute to the development of microvascular complications. For example, the treatment of dyslipidemia and hypertension has been shown to affect the development of these complications. Still, the most powerful and common measure used in long term glucose control and its complications is HbA1c measurement.

Many studies have been undertaken to examine what the optimal levels of HbA1c are. However, there are still unknowns around the understanding of how glycemic control and variability interacts with patient specific factors including age, comorbid conditions, and the duration of diabetes. This entails more studies to be done that seek to develop better ways of managing microvascular complications burden in T2DM patients.

Methodology

Study Design and Setting

This retrospective observational study was conducted in a tertiary care hospital, leveraging clinical data collected from patients diagnosed with type 2 diabetes mellitus (T2DM). The study aimed to investigate the correlation between glycated hemoglobin (HbA1c) levels and the prevalence of microvascular complications, including diabetic retinopathy (DR), nephropathy (DN), and neuropathy.

Study Population

The study included adult patients aged 18 years and older who were diagnosed with T2DM and had received care at the hospital. Patients were selected based on the following inclusion and exclusion criteria:

- Inclusion Criteria:
  - Diagnosed with T2DM based on American Diabetes Association (ADA) criteria.
  - Availability of HbA1c measurements within the study period.
  - Documented presence or absence of microvascular complications (DR, DN, or neuropathy).

- Exclusion Criteria:
  - Patients with type 1 diabetes or other forms of diabetes.
  - Incomplete medical records or missing HbA1c data.
  - Patients with severe comorbid conditions that could independently affect microvascular outcomes (e.g., advanced renal failure unrelated to diabetes).

Data Collection

Data were extracted from the hospital's electronic medical records (EMR) system. The following variables were collected:

- Demographic data: Age, sex, duration of diabetes.
- Laboratory parameters: HbA1c levels, fasting blood glucose, serum creatinine, and estimated glomerular filtration rate (eGFR).
- Clinical data: Documentation of DR (confirmed by fundoscopic examination), DN (based on urinary albumin-to-creatinine ratio or eGFR), and neuropathy (confirmed by nerve conduction studies or clinical examination).
- Comorbid conditions: Hypertension, dyslipidemia, and cardiovascular disease.

Study Groups

Patients were stratified into three groups based on their most recent HbA1c levels:

- Group 1: HbA1c <7%
- Group 2: HbA1c 7–9%
- Group 3: HbA1c >9%

Outcome Measures

The primary outcome was the prevalence of microvascular complications (DR, DN, and neuropathy) across the three HbA1c groups. Secondary outcomes included the association between duration of diabetes, HbA1c variability, and the severity of complications.

Statistical Analysis

Descriptive statistics were used to summarize the demographic and clinical characteristics of the study population. Continuous variables were presented as means ±standard deviation (SD), and categorical variables as frequencies and percentages.

- The correlation between HbA1c levels and microvascular complications was assessed using Pearson's correlation coefficient.
- Logistic regression analysis was performed to evaluate the odds of developing each complication based on HbA1c levels, adjusted for potential confounders such as age, duration of diabetes, and comorbidities.
- A one-way ANOVA test was conducted to compare the mean HbA1c levels across patients with varying severities of microvascular complications.

Ethical Considerations

Ethical approval for the study was obtained from the ethics committee. Informed consent was waived as the study utilized anonymized retrospective data. All procedures adhered to the ethical principles outlined in the Declaration of Helsinki.

Findings

The research consisted of 400 patients suffering from type 2 diabetes mellitus (T2DM) and sought to determine the relationship between microvascular complications such as retinopathy, nephropathy, and neuropathy with the levels of HbA1c. The results are presented below.

Summary of Microvascular Complications by HbA1c Group

The prevalence of microvascular complications increased significantly across HbA1c groups. Patients with HbA1c levels >9% had the highest prevalence of complications, while those with HbA1c <7% exhibited the lowest.

HbA1c Group	Number of Patients	Prevalence of Retinopathy (%)	Prevalence of Nephropathy (%)	Prevalence of Neuropathy (%)
<7%	120	15	10	8
7-9%	180	35	30	25
>9%	100	60	55	50

Logistic Regression Analysis

Logistic regression analysis demonstrated a significant association between HbA1c levels and each microvascular complication. The odds of developing retinopathy, nephropathy, and neuropathy were notably higher in patients with elevated HbA1c levels, with statistically significant p-values.

Complication	Odds Ratio (OR)	95% CI (Lower)	95% CI (Upper)	p-value
Retinopathy	2.1	1.5	2.9	0.001
Nephropathy	3.2	2.3	4.4	0.0001
Neuropathy	4.0	3.0	5.2	0.00001

Key Observations

1. Patients with HbA1c >9% were three times more likely to develop retinopathy and nephropathy compared to those with HbA1c <7%.
2. Neuropathy was significantly associated with higher HbA1c levels, with the strongest odds ratio (4.0).
3. The relationship between HbA1c and microvascular complications was consistent across all complication types, reinforcing the importance of optimal glycemic control.

These results highlight the critical need for maintaining HbA1c levels below 7% to reduce the risk of microvascular complications in T2DM.

Discussion

The results of this study show an important relationship between HbA1c levels and microvascular complications in patients suffering from type 2 diabetes mellitus (T2DM). Higher levels of HbA1c among patients were associated with a higher frequency of diabetic retinopathy (DR), nephropathy (DN), and neuropathy, thus emphasizing the importance of controlling glycemic levels to avoid these complications.

Interpretation of Results

In the context of this study, the findings are similar to other studies conducted by Teliti et al. (2018) and Klein et al. (1996), which establish that poor glycemic control exacerbated the risk of microvascular complications. As hypothesized, the severity of complications was more pronounced to the patients who had a higher than 9% of HbA1c, thus pointing out the potential threshold effect of hyperglycemia.

These findings were further supported by logistic regression, which demonstrated significant odds ratios for all three complications. For example, evidence from Zoungas et al. (2012) corroborated that the likelihood of developing neuropathy was four times higher among patients with elevated diabetes burden. This presumes that not only is the average HbA1c maintained at a plausible level, but also that an increase in microvascular damage is associated with hyperglycemic variability.

Clinical Considerations

Results suggest that achieving target HbA1c levels of less than 7% is recommended. Maintaining such levels minimizes the incidence of micro vascular complications. There is need, how ever, to individualize targets to prevent hypoglycemic episodes, which are more frequent in the elderly, those with comorbidities, or having aggressive management of diabetes. These results support current guidelines from the American Diabetes Association, which recommend a target HbA1c of <7% for most patients while considering less stringent targets for specific populations.

Another important aspect of the study is to emphasize the importance of bi annual screening for diabetic retinopathy, diabetic neuropathy, and in patients with inadequate glycemic control. The screening will enable early detection of the conditions and facilitate prompt corrective measures in order to avert

complications. In addition, the management of other risk factors such as high blood pressure and high cholesterol coupled with poor diabetic control will minimize the overall complications.

Strengths and Limitations

Some notable strengths of this study are the large sample size, comprehensive data collection, and orientation to the tertiary care level, all of which guarantee the heterogeneity of the patients. Certain limitations should also be mentioned. First, the retrospective design does not allow the assessment of causation. Second, there are problems of missing values or data quality issues because of overdependence on electronic medical records. Third, the study did not consider the changes in microvascular complications over the duration of time and HbA1c within a single period of time.

Future Directions

Further research should provide insight into the impact of newer therapeutic agents such as SGLT2 inhibitors and GLP-1 receptor agonists on microvascular complications and HbA1c variability. Also, there should be additional studies focusing on the ramifications of tight glycemic control on microvascular outcomes regarding its term effects.

Conclusion

To conclude, findings from this study provide evidence supporting the relationship between high HbA1c levels and microvascular complications in Type 2 Diabetes Mellitus patients (T2DM). These results substantiate the importance of glycemic control to avert complications of T2DM and further highlight the need for more personalized treatment plans. There is a need for further investigation regarding the existing gaps to refine the management of microvascular complications among patients suffering from T2DM.

References:

1. Teliti, M., Cogni, G., Sacchi, L., Dagliati, A. (2018). Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients.
2. Klein, R., Klein, B. E. K., Moss, S. E. (1996). Relation of glycemic control to diabetic microvascular complications in diabetes mellitus.
3. Timar, B., Albai, O. (2012). The relationship between hemoglobin A1c and chronic complications in diabetes mellitus.
4. Hirsch, I. B., Brownlee, M. (2010). Beyond hemoglobin A1c—need for additional markers of risk for diabetic microvascular complications.
5. Zhao, L., Ma, J., Wang, S., Xie, Y. (2015). Relationship between β-cell function, metabolic control, and microvascular complications in type 2 diabetes mellitus.
6. Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M. E. (2012). Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycemic thresholds.